AMH Equity Ltd Trims Holdings in iCAD, Inc. (NASDAQ:ICAD)

AMH Equity Ltd reduced its stake in iCAD, Inc. (NASDAQ:ICAD) by 53.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 136,643 shares of the technology company’s stock after selling 159,409 shares during the quarter. AMH Equity Ltd owned approximately 0.51% of iCAD worth $250,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ICAD. Summit Trail Advisors LLC acquired a new position in shares of iCAD during the 4th quarter valued at about $214,000. Thompson Davis & CO. Inc. acquired a new stake in iCAD during the fourth quarter worth about $31,000. Finally, waypoint wealth counsel raised its stake in iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after purchasing an additional 4,400 shares during the period. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Stock Performance

Shares of iCAD stock opened at $2.52 on Thursday. iCAD, Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The firm has a market capitalization of $66.88 million, a price-to-earnings ratio of -19.38 and a beta of 1.47. The stock has a 50 day moving average of $2.51 and a 200 day moving average of $1.97.

Analyst Ratings Changes

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, February 20th.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.